SL-scan identifies synthetic lethal interactions in cancer using metabolic networks
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Exploiting synthetic lethality is a promising strategy for developing targeted cancer therapies. However, identifying clinically significant synthetic lethal (SL) interactions among a large number of gene combinations is a challenging computational task. In this study, we developed the SL-scan pipeline based on metabolic network modeling to discover SL interaction. The SL-scan pipeline identifies the association between simulated Flux Balance Analysis knockout scores and mutation data across cancer cell lines and predicts putative SL interactions. We assessed the concordance of the SL pairs predicted by SL-scan with those of obtained from analysis of the CRISPR, shRNA, and PRISM datasets. Our results demonstrate that the SL-scan pipeline outperformed existing SL prediction approaches based on metabolic networks in identifying SL pairs in various cancers. This study emphasizes the importance of integrating multiple data sources, particularly mutation data, when identifying SL pairs for targeted cancer therapies. The findings of this study may lead to the development of novel targeted cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This challenge is especially pronounced in oncology, where identifying cancer vulnerabilities and dependencies, such as synthetic lethality relationships, is vital for developing precision therapies (1, 2, 3).”
From DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay (2026) · cites this paper as [2]
In the citing paper
“Despite significant advances, a major challenge remains in the precise characterization of drug targets and off-targets within complex cellular environments.”
From DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay (2026) · cites this paper as [2]
In the citing paper
“It also informs the design and prioritization of synthetic-lethal strategies (2), offering a valuable layer of evidence for translational research.”
From DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay (2026) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
Corsello, S. M., Nagari, R. T., Spangler, R. D., Rossen, J., Kocak, M., Bryan, J. G., Humeidi, R., Peck, D., Wu, X., Tang, A. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0018-6 · Cited by 878
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase
Frezza, C., Zheng, L., Folger, O., Rajagopalan, K. N., MacKenzie, E. D., Jerby, L., Micaroni, M., Chaneton, B., Adam, J., Hedley, A., et al. (2011) · Nature · doi:10.1038/nature10363 · Cited by 503
Systems Biology: Constraint-based Reconstruction and Analysis
Palsson, B. Ø. (2015) · doi:10.1017/cbo9781139854610 · Cited by 210
SYNTHETIC LETHALITY AND SEMI-LETHALITY AMONG FUNCTIONALLY RELATED MUTANTS OF DROSOPHILA MELANOGASTER
Lucchesi, J. C. (1968) · Genetics · doi:10.1093/genetics/59.1.37 · Cited by 139
Research works printed but not linked: 48
- Zhao, W. et al. Large-scale characterization of drug responses of clinically relevant proteins in cancer cell lines. Cancer Cell 38, 829-843.e4 (2020). · DOI
- Srivatsa, S. et al. Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens. Nat. Commun. 13, 7748 (2022). · DOI
- Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017). · DOI · Paper page
- Montazeri, H. et al. Systematic identification of novel cancer genes through analysis of deep shRNA perturbation screens. Nucleic Acids Res. 49, 8488–8504 (2021). · DOI · Paper page
- Lin, C.-H. & Lichtarge, O. Using interpretable deep learning to model cancer dependencies. Bioinformatics 37, 2675–2681 (2021). · DOI
- Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564-576.e16 (2017). · DOI · Paper page
- Iglehart, J. D. & Silver, D. P. Synthetic lethality–a new direction in cancer-drug development. N. Engl. J. Med. 361, 189–191 (2009). · DOI · Paper page
- Lord, C. J. & Ashworth, A. PARP Inhibitors: the first synthetic lethal targeted therapy. Science 355, 1152 (2017). · DOI · Paper page
- Li, S. et al. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduct Target Ther 5, 241 (2020). · DOI · Paper page
- Shieh, G. S. Harnessing synthetic lethal interactions for personalized medicine. J Pers Med 12, (2022). · DOI
- Bender, A. & Pringle, J. R. Use of a screen for synthetic lethal and multicopy suppressee mutants to identify two new genes involved in morphogenesis in Saccharomyces cerevisiae. Mol. Cell. Biol. 11, 1295–1305 (1991).
- Sinha, S. et al. Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nat. Commun. 8, 15580 (2017). · DOI
- Yizhak, K. et al. Phenotype-based cell-specific metabolic modeling reveals metabolic liabilities of cancer. Elife 3, (2014). · DOI · Paper page
- Agren, R. et al. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol. Syst. Biol. 10, 721 (2014). · DOI · Paper page
- Paul, A. et al. Exploring gene knockout strategies to identify potential drug targets using genome-scale metabolic models. Sci. Rep. 11, 213 (2021). · DOI
- Apaolaza, I. et al. An in-silico approach to predict and exploit synthetic lethality in cancer metabolism. Nat. Commun. 8, 459 (2017). · DOI
- Bidkhori, G. et al. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc. Natl. Acad. Sci. U. S. A. 115, E11874–E11883 (2018). · DOI · Paper page
- Sun, L., Suo, C., Li, S.-T., Zhang, H. & Gao, P. Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. Biochim. Biophys. Acta Rev. Cancer 1870, 51–66 (2018). · DOI · Paper page
- von Kamp, A. & Klamt, S. Enumeration of smallest intervention strategies in genome-scale metabolic networks. PLoS Comput. Biol. 10, e1003378 (2014). · DOI · Paper page
- Apaolaza, I. et al. A network-based approach to integrate nutrient microenvironment in the prediction of synthetic lethality in cancer metabolism. PLoS Comput. Biol. 18, e1009395 (2022). · DOI
- Hartman, H. B. et al. Identification of potential drug targets in Salmonella enterica sv. Typhimurium using metabolic modelling and experimental validation. Microbiology 160, 1252–1266 (2014). · DOI
- Navid, A. Applications of system-level models of metabolism for analysis of bacterial physiology and identification of new drug targets. Brief. Funct. Genomics 10, 354–364 (2011). · DOI
- Pratapa, A., Balachandran, S. & Raman, K. Fast-SL: an efficient algorithm to identify synthetic lethal sets in metabolic networks. Bioinformatics 31, 3299–3305 (2015). · DOI
- Ghandi, M. et al. Next-generation characterization of the cancer cell line Encyclopedia. Nature 569, 503–508 (2019). · DOI · Paper page
- Noronha, A. et al. The Virtual Metabolic Human database: integrating human and gut microbiome metabolism with nutrition and disease. Nucleic Acids Res. 47, D614–D624 (2019). · DOI · Paper page
- Jamialahmadi, O., Hashemi-Najafabadi, S., Motamedian, E., Romeo, S. & Bagheri, F. A benchmark-driven approach to reconstruct metabolic networks for studying cancer metabolism. PLoS Comput. Biol. 15, e1006936 (2019). · DOI
- Orth, J. D., Thiele, I. & Palsson, B. Ø. What is flux balance analysis?. Nat. Biotechnol. 28, 245–248 (2010). · DOI · Paper page
- Joshi, C. J. et al. StanDep: Capturing transcriptomic variability improves context-specific metabolic models. PLoS Comput. Biol. 16, e1007764 (2020).
- Zur, H., Ruppin, E. & Shlomi, T. iMAT: an integrative metabolic analysis tool. Bioinformatics 26, 3140–3142 (2010). · DOI · Paper page
- Opdam, S. et al. A Systematic evaluation of methods for tailoring genome-scale metabolic models. Cell Syst 4, 318-329.e6 (2017). · DOI · Paper page
- Shao, D. D. et al. ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res. 23, 665–678 (2013). · DOI · Paper page
- Gao, Y. et al. Knockdown of RRM1 in tumor cells promotes radio-/chemotherapy induced ferroptosis by regulating p53 ubiquitination and p21-GPX4 signaling axis. Cell Death Discov 8, 343 (2022). · DOI
- Shu, Z. et al. Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition. Oncogene 39, 5721–5733 (2020). · DOI
- Ramamoorthy, K., Sabui, S., Manzon, K. I., Balamurugan, A. N. & Said, H. M. miR-122–5p is involved in post-transcriptional regulation of the mitochondrial thiamin pyrophosphate transporter (SLC25A19) in pancreatic acinar cells. American Journal of Physiology-Gastrointestinal and Liver Physiology (2023) doi:https://doi.org/10.1152/ajpgi.00106.2023. · DOI
- Chen, X. et al. STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1. Oncogene 41, 2492–2504 (2022). · DOI
- Henkels, K. M., Muppani, N. R. & Gomez-Cambronero, J. PLD-specific small-molecule inhibitors decrease tumor-associated macrophages and neutrophils infiltration in breast tumors and lung and liver metastases. PLoS ONE 11, e0166553 (2016). · DOI · Paper page
- Brown, H. A., Thomas, P. G. & Lindsley, C. W. Targeting phospholipase D in cancer, infection and neurodegenerative disorders. Nat. Rev. Drug Discov. 16, 351–367 (2017). · DOI · Paper page
- Kadlubar, F. F. et al. The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol. Biomarkers Prev. 12, 327–331 (2003).
- Huang, H. et al. SLC15A4 serves as a novel prognostic biomarker and target for lung adenocarcinoma. Front. Genet. 12, 666607 (2021).
- Li Petri, G. et al. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. Br. J. Cancer 123, 644–656 (2020). · DOI
- Sharaf, R. N. et al. Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes. BMC Gastroenterol. 11, 5 (2011). · DOI
- Bang, Y.-J. Capecitabine in gastric cancer. Expert Rev. Anticancer Ther. 11, 1791–1806 (2011). · doi:10.1586/era.11.172
- Okines, A., Chau, I. & Cunningham, D. Capecitabine in advanced gastric cancer. Expert Opin. Pharmacother. https://doi.org/10.1517/14656566.8.16.2851 (2007). · DOI
- Wang, J. et al. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene 40, 4894–4905 (2021). · DOI
- Choksi, A. et al. Tumor suppressor SMAR1 regulates PKM alternative splicing by HDAC6-mediated deacetylation of PTBP1. Cancer Metab 9, 16 (2021). · DOI
- Xiao, D. et al. Inhibitory role of proguanil on the growth of bladder cancer via enhancing EGFR degradation and inhibiting its downstream signaling pathway to induce autophagy. Cell Death Dis. 13, 499 (2022). · doi:10.1038/s41419-022-04937-z
- Zhang, N., Sundquist, J., Sundquist, K. & Ji, J. Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study. BMC Med. 20, 1–10 (2022). · DOI
- Sun, J. et al. Whole transcriptome analysis of chemically induced hepatocellular carcinoma using RNA-sequencing analysis. FEBS Open Bio 9, 1900–1908 (2019). · DOI
Cited by
DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay
Zangene, E., Gholizadeh, E., Schwämmle, V., Saei, A. A., Wilhelm, M., Käll, L., & Jafari, M. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101603 · Cited by 3
Self-citation
Metadata
- Authors
- Zangene, E., Marashi, S.-A., & Montazeri, H.
- Venue
- Scientific Reports
- Published
- 2023-09-22
- Volume
- 13
- Issue
- 1
- ISSN
- 2045-2322
- Cited by
- 8
- References
- 5
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SL-scan identifies synthetic lethal interactions in cancer using metabolic networks. https://app.cochat.ai/papers/10.1038/s41598-023-42992-4
- The paper
- Zangene, E., Marashi, S.-A., & Montazeri, H. (2023). SL-scan identifies synthetic lethal interactions in cancer using metabolic networks. Scientific Reports. https://doi.org/10.1038/s41598-023-42992-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.